Tesamorelin trial data – does it really cut visceral fat for non‑HIV users?

Question

This is an NCBI clinical review report that pulls together the Phase 3 LIPO‑010 and LIPO‑011 studies of tesamorelin in HIV‑positive adults with antiretroviral‑related lipodystrophy. It highlights the 8‑16% reduction in visceral adipose tissue after 26 weeks and the accompanying IGF‑1 rises. For me the numbers look solid but the cohort is very specific – HIV patients on ART with already elevated visceral fat. I’ve never seen that kind of fat loss with ipamorelin or MK‑677 in healthy guys; my own experience is more about sleep quality and modest recovery tweaks. I wonder if the mechanism is mainly driven by the abnormal metabolic milieu in those patients rather than a pure GH effect. Has anyone here tried tesamorelin off‑label for body composition and actually measured a comparable VAT drop, or does it seem more like a placebo effect outside the HIV context? Also, what dosing have you found hits saturation without excessive IGF‑1 spikes?

tiredmira · Accepted Answer

Yeah, I've been digging into this too. The HIV cohort data is pretty clean, but I agree the population is so specific that translating it to healthy users is a real stretch. My understanding is tesamorelin has GHRH action specifically, so it pulses your own GH rather than mimicking it, which theoretically should be gentler on IGF-1 than something like MK-677. Curious if anyone has actually run DEXA or MRI tracking before and after, because scale weight and even waist measurements don't really capture visceral change well. Without imaging it's basically guesswork 😅

runner_aaron · Answer

Howzit. True, imaging is the only real way to know. Question for the room though: how long would you actually need to run tesamorelin before a follow-up scan would show anything meaningful? 12 weeks, 26, longer? I’ve heard the lipo trials went 26 but that feels like a long commitment just to get a number on paper, and IGF-1 creeping up the whole time is its own thing tbh.

fasted_scientist · Answer

Fair play, the imaging bit is a good shout. Most clinics near me quote MRI at £400+ a session which is mental when you're trying to track a few percent change over months. What numbers actually made you pull the trigger on tesamorelin in the end, ngl? Was it the LIPO trial cohort specifically or did you find any data in healthy adults?

fasted_scientist · Answer

Ngl you are spot on about the imaging bit. I reckon trying to track visceral fat changes with just a tape measure is a bit of a joke. I have only ever used a scale and noticed my waist felt slightly less bloated, but that could just be water weight or something. If someone actually did a DEXA scan while running this, do you reckon the fat loss would be as significant as the HIV studies suggest?

grinder265 · Answer

Yeah the GHRH vs ghrelin mimetic distinction is what got me looking at tesamorelin in the first place, ngl. And you're right, pulse vs sustained GH release is a totally different endocrine picture on paper. DEXA wont really cut it for visceral either, you'd need a proper MRI or at minimum a DEXA with the visceral fat estimate which most places dont even run. Scan costs make it basically a research-only thing for most people.

fasted_scientist · Answer

Honestly 26 weeks feels like the floor based on those trials, and a mate who tried it off-label said his DEXA at 3 months was basically a waste of money cos the change was so small. IGF-1 does creep the whole time you're on it, which is part of why I'd want proper bloods before committing. If I were doing it I'd probably want a baseline scan, 26 weeks minimum, then another scan, and stop if IGF-1 goes silly. The cost of that over 6 months is a big ask for something that might not work in a healthy person tbh. What was your plan, just bloods or were you thinking imaging too?

Tesamorelin trial data – does it really cut visceral fat for non‑HIV users?

Comments